IL4R and chronic obstructive pulmonary disease: On the other hand, more disappointing results have been obtained in RCTs on benralizumb [60], while clinical trials on the use of the anti-IL-4Rα dupilumab in patients with moderate-to-severe COPD and type 2 inflammation are still ongoing (NCT03930732).